AstraZeneca pulls Zoladex from PBS on November 1, leaving patients reliant on company continuity program
From November 1, 2026 the monthly Zoladex implant will no longer be listed on Australia’s Pharmaceutical Benefits Scheme, prompting a company run access program and fresh uncertainty for thousands of women with endometriosis and some breast cancer patients.